Status:
UNKNOWN
Notify 2: An Evaluation of the Impact of Notification of Incidental Coronary Artery Calcium on Statin Rates
Lead Sponsor:
Stanford University
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
The primary objective is to estimate the impact of notification of primary care provider and patient of at least moderate incidental coronary artery calcification (CAC) on a prior non-gated chest CT o...
Eligibility Criteria
Inclusion
- Age greater than or equal to 18 and less than 85
- Non-gated chest CT from 1/1/2016-6/30/2020 with algorithm screening estimating CAC score of at least 100 Agatston Units with radiologist confirmation of moderate or severe CAC
- Encounter with Palo Alto VA affiliated primary care since 2020
Exclusion
- Prior diagnosis of coronary artery disease, peripheral artery disease, or cerebrovascular disease
- Dementia
- Metastatic cancer or active cancer undergoing chemotherapy
- CT coronary angiogram since 2016
- Invasive Coronary angiogram since 2016
- CAC scan since 2016
- Statin therapy within prior 6 months
- Prior ezetimibe or PCSK9 inhibitor therapy
- Prior rhabdomyolysis with statin therapy
- Schizophrenia
- Substance abuse disorder (alcohol, amphetamines, cocaine, opioids)
- Hospice
- Pregnancy
Key Trial Info
Start Date :
August 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 15 2023
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT05394181
Start Date
August 1 2022
End Date
March 15 2023
Last Update
May 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Palo Alto Veteran's Affairs Hospital
Palo Alto, California, United States, 94304